GLP-1 weight-loss drugs have been major revenue generators for pharmaceutical companies such as Eli Lilly (LLY) and Novo Nordisk (NVO). Goldman Sachs US Lead...
). Goldman Sachs US Lead Biotechnology Analyst Salveen Richter joins Catalysts to discuss the state of the weight-loss market and the potential headwinds for these pharmaceutical companies .She notes that Eli Lilly and Novo Nordisk are facing limited supply as demand skyrockets.
And then we're watching Regeneron as a player going after the quality or body proportionality of weight loss.So they're trying to address that side of the story. Um So I think when we start to see them expand on manufacturing, but also these new entrants coming in who have manufacturing capa capacity like Amgen talked about at length about their ability to manufacture here that should kind of aid and also you'll have a differentiated approach, right?So I mean, when it comes to the ability to meet that demand, right?What every what so many of these bigger players are doing, trying to address that.
And so I think there's going to be significant investment, maybe there's a way to use contract manufacturing organizations and bring them into the process here.
Eli Lilly Pharmaceutical Companies Salveen Richter Goldman Sachs
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly exec on weight-loss drugs: 'It's not just a flash in the pan'Eli Lilly may be riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound — which Wall Street estimates could net the company $13.5...
Read more »
FDA panel votes unanimously for Eli Lilly's Alzheimer's treatmentAn FDA panel voted unanimously to support Eli Lilly's Alzheimer's drug for use in adults 60-85 years old.
Read more »
FDA panel votes to recommend Eli Lilly's Alzheimer's drugA US Food and Drug Administration (FDA) panel voted unanimously 11-0 to recommend the approval of Eli Lilly's (LLY) Alzheimer's drug, donanemab. Yahoo...
Read more »
Eli Lilly's new Alzheimer's treatment could 'lift' drug marketEli Lilly (LLY) is one step closer to getting its new Alzheimer's treatment approved by the Food and Drug Administration (FDA) after a panel voted to...
Read more »
Eli Lilly commits $5.3B to up weight-loss drug productionEli Lilly and Company (LLY) announced today that it has committed more than $5.3 billion to its Lebanon, Indiana, manufacturing site, more than doubling its ...
Read more »
China Clears Eli Lilly’s Weight-Loss Drug, Only for Diabetes NowChina gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will intensify the drugmaker’s rivalry with Novo Nordisk A/S over weight-loss drugs in the world’s second-largest market.
Read more »